- On 25 March 2026, FormFactor, Inc. and Rohde & Schwarz announced a co-marketing partnership under the MeasureOne program to deliver validated, turnkey on-wafer RF test systems that integrate FormFactor’s probing platforms with Rohde & Schwarz’s vector network analyzers, signal analyzers, and generators up to the THz range.
- This collaboration creates an integrated workflow that can help chipmakers detect RF device issues at the wafer stage, potentially lowering test integration effort, reducing scrap before packaging, and improving confidence in product performance across demanding applications like 5G frontends and advanced filters.
- Next, we’ll examine how this deeper integration of RF instrumentation and on-wafer probing could influence FormFactor’s investment narrative and long-term positioning.
We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
FormFactor Investment Narrative Recap
To own FormFactor, you need to believe it can convert its test and measurement expertise into resilient margins despite product mix, cost inflation, and customer concentration. The Rohde & Schwarz MeasureOne partnership strengthens its RF and high frequency test offering, but on its own does not materially change the near term margin pressure risk or the importance of stabilizing earnings from volatile DRAM and HBM demand.
The recent launch of the Flatiron benchtop dilution refrigerator is particularly relevant here, because it highlights FormFactor’s push into advanced cryogenic test for emerging applications like quantum and ultra low temperature RF characterization. Together with the Rohde & Schwarz collaboration, it underscores a broader effort to deepen system level test capabilities that could support FormFactor’s longer term positioning if these higher value segments scale as expected.
Yet, against these promising RF and cryogenic test moves, investors should still be mindful of how ongoing gross margin pressure and elevated manufacturing costs could...
Read the full narrative on FormFactor (it's free!)
FormFactor’s narrative projects $984.3 million revenue and $97.0 million earnings by 2028.
Uncover how FormFactor's forecasts yield a $84.11 fair value, a 18% downside to its current price.
Exploring Other Perspectives
While the new RF partnership may support the idea of stronger long term positioning, the most pessimistic analysts were only assuming about US$925.3 million of revenue and US$91.3 million of earnings by 2028, which contrasts sharply with the more upbeat view that advanced test demand alone can offset mix, tariff and cost risks.
Explore 6 other fair value estimates on FormFactor - why the stock might be worth less than half the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your FormFactor research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
- Our free FormFactor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate FormFactor's overall financial health at a glance.
Want Some Alternatives?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com